RxDoctor Payments Data

Kathryn Kincaide, NP

Family · Lee's Summit, MONPI 1639584790

Payments from drug & device makers

$3,910in general payments, 2019–2025

Across 214 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$880
  • Boehringer Ingelheim$470
  • GSK$460
  • Grifols USA, LLC$405
  • Sanofi$311
  • Regeneron Healthcare Solutions, Inc.$149
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,910100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,910 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$30,683
Medicare patients
183
Services billed
330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter401$332,590
Breztri AerosphereBudesonide/Glycopyr/Formoterol241$170,846
XolairOmalizumab39$151,442
NucalaMepolizumab29$106,746
Stiolto RespimatTiotropium Br/Olodaterol Hcl121$105,562
Prolastin CAlpha-1-Proteinase Inhibitor11$95,175
Spiriva RespimatTiotropium Bromide94$74,126
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr130$68,818
Breo ElliptaFluticasone/Vilanterol135$61,685
SymbicortBudesonide/Formoterol Fumarate129$45,562
Spiriva HandihalerTiotropium Bromide53$37,223
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate100$17,514
Albuterol Sulfate HfaAlbuterol Sulfate659$16,321
Fluticasone-SalmeterolFluticasone Propion/Salmeterol86$16,167
XareltoRivaroxaban13$11,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$460$585,379740 claims
AstraZenecaBreztri Aerosphere, Symbicort$880$216,408370 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$470$179,689215 claims
Grifols USA, LLCProlastin C$405$95,17511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Lee's Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →